{"calculatePct":false,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"0"}]}],"title":"Complete Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"},{"groupId":"OG005","value":"4"},{"groupId":"OG006","value":"0"}]}],"title":"Partial Response"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"},{"groupId":"OG005","value":"5"},{"groupId":"OG006","value":"0"}]}],"title":"Stable Disease"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"},{"groupId":"OG005","value":"1"},{"groupId":"OG006","value":"2"}]}],"title":"Progression of Disease"}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"},{"groupId":"OG005","value":"14"},{"groupId":"OG006","value":"2"}],"units":"Participants"}],"description":"Per Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0) for target lesions and assessed by MRI and/or CT: Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Stable Disease (SD), neither sufficient shrinkage to qualify for a Partial Response nor sufficient increase to qualify for Progression of Disease (POD); POD, 20% increase in the sum of the longest diameter of target lesions, or a measurable increase in a non-target lesion, or the appearance of new lesions; Complete Response (CR), Disappearance of all target lesions.","groups":[{"description":"Bendamustine 70 mg/m2, ABT-888 50 mg","id":"OG000","title":"Dose Level 1-Bendamustine 70 mg/m2, ABT-888 50 mg"},{"description":"Bendamustine 90 mg/m2, ABT-888 50 mg","id":"OG001","title":"Dose Level 2: Bendamustine 90 mg/m2, ABT-888 50 mg"},{"description":"Bendamustine 90 mg/m2, ABT-888 100 mg BID","id":"OG002","title":"Dose Level 3: Bendamustine 90 mg/m2, ABT-888 100 mg BID"},{"description":"Bendamustine 90 mg/m2, ABT-888 150 mg BID","id":"OG003","title":"Dose Level 4: Bendamustine 90 mg/m2, ABT-888 150 mg BID"},{"description":"Bendamustine 90 mg/m2, ABT-888 200 mg BID","id":"OG004","title":"Dose Level 5: Bendamustine 90 mg/m2, ABT-888 200 mg BID"},{"description":"Bendamustine 90 mg/m2, ABT-888 300 mg BID","id":"OG005","title":"Dose Level 6: Bendamustine 90 mg/m2, ABT-888 300 mg BID"},{"description":"Bendamustine 90 mg/m2, ABT-888 400 mg BID","id":"OG006","title":"Dose Level 7: Bendamustine 90 mg/m2, ABT-888 400 mg BID"}],"paramType":"COUNT_OF_PARTICIPANTS","reportingStatus":"POSTED","timeFrame":"2 years","title":"Response Rate","type":"PRIMARY","unitOfMeasure":"Participants"}